

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

1 Selected Articles from This Issue

MCT FIRST DISCLOSURES

- 3 SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance**
Kristen Jensen-Pergakes, John Tatlock, Karen A. Maegley, Indrawan J. McAlpine, Michele McTigue, Tao Xie, Christopher P. Dillon, Yuli Wang, Shinji Yamazaki, Noah Spiegel, Manli Shi, Amy Nemeth, Natalie Miller, Eleanore Hendrickson, Hieu Lam, John Sherrill, Chi-Yeh Chung, Elizabeth A. McMillan, Shannon Karlicek Bryant, Prakash Palde, John Braganza, Alexei Brooun, Ya-Li Deng, Vesta Goshtasbi, Susan E. Kephart, Robert A. Kumpf, Wei Liu, Ryan L. Patman, Eugene Rui, Stephanie Scales, Michelle Tran-Dube, Fen Wang, Martin Wythes, and Thomas A. Paul

REVIEWS

- 16 Exploiting Canonical TGF β Signaling in Cancer Treatment**
Qi Liu, Genwen Chen, Jade Moore, Ines Guix, Dimitris Placantonakis, and Mary Helen Barcellos-Hoff
- 25 DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy**
Gamze Bildik, Xiaowen Liang, Margie N. Sutton, Robert C. Bast Jr, and Zhen Lu

SMALL MOLECULE THERAPEUTICS

- 38 AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer**
Yuqing Zhang, Emily N. Arner, Ali Rizvi, Jason E. Toombs, Huocong Huang, Steven L. Warner, Jason M. Foulks, and Rolf A. Brekken

48 Triple Targeting of Breast Tumors Driven by Hormonal Receptors and HER2

Elena Shagisultanova, Lyndsey S. Crump, Michelle Borakove, Jessica K. Hall, Aryana R. Rasti, Benjamin A. Harrison, Peter Kabos, Traci R. Lyons, and Virginia F. Borges

58 Targeting CD99 Compromises the Oncogenic Effects of the Chimera EWS-FLI1 by Inducing Reexpression of Zyxin and Inhibition of GLI1 Activity

Tommaso Balestra, Maria Cristina Manara, Maria Antonella Laginestra, Michela Pasello, Alessandra De Feo, Cristian Bassi, Clara Guerzoni, Lorena Landuzzi, Pier-Luigi Lollini, Davide Maria Donati, Massimo Negrini, Mauro Magnani, and Katia Scotlandi

70 The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity *In Vitro* and *In Vivo*

Katja Klausz, Christian Kellner, Carina Lynn Gehlert, Steffen Krohn, Hauke Wilcken, Inken Floerkemeier, Andreas Günther, Dirk O. Bauerschlag, Bernd Clement, Martin Gramatzki, and Matthias Peipp

79 Radiosensitizing Pancreatic Cancer via Effective Autophagy Inhibition

Taha Yazal, Justine Bailleul, Yangjingyi Ruan, David Sung, Fang-I Chu, Daisy Palomera, Amy Dao, Anahita Sehgal, Vibha Gurunathan, Laila Aryan, Mansoureh Eghbali, and Erina Vlashi

89 Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas

Magdalena Klanova, Dmitry Kazantsev, Eva Pokorna, Tomas Zikmund, Jana Karolova, Matej Behounek, Nicol Renesova, Dana Sovilj, Cristina D. Kelemen, Karel Helman, Radek Jaksa, Ondrej Havranek, Ladislav Andera, Marek Trneny, and Pavel Klener

100 The Mitochondrial Disruptor Devimistat (CPI-613) Synergizes with Genotoxic Anticancer Drugs in Colorectal Cancer Therapy in a Bim-Dependent Manner

Carina Arnold, Philipp Demuth, Nina Seiwert, Simon Wittmann, Kerstin Boengler, Birgit Rasenberger, Markus Christmann, Magdalena Huber, Thomas Brunner, Michael Linnebacher, and Jörg Fahrner

TABLE OF CONTENTS

LARGE MOLECULE THERAPEUTICS

- 113 A FZD7-specific Antibody-Drug Conjugate Induces Ovarian Tumor Regression in Preclinical Models**
Myan Do, Christina C.N. Wu, Pooja R. Sonavane, Edwin F. Juarez, Stephen R. Adams, Jason Ross, Alessandra Rodriguez y Baena, Charmi Patel, Jill P. Mesirov, Dennis A. Carson, Sunil J. Advani, and Karl Willert
- 125 Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal Carcinomatosis**
Christopher S. Chandler, Meghan M. Bell, Sebastian K. Chung, Darren R. Veach, Edward K. Fung, Blesida Punzalan, Daniela Burnes Vargas, Mitesh Patel, Hong Xu, Hong-fen Guo, Brian H. Santich, Pat B. Zanzonico, Sébastien Monette, Garrett M. Nash, Andrea Cercek, Achim Jungbluth, Neeta Pandit-Taskar, Nai Kong V. Cheung, Steven M. Larson, and Sarah M. Cheal
- 138 Enhanced Antitumor Responses of Tumor Antigen-Specific TCR T Cells Genetically Engineered to Produce IL7 and CCL19**
Yoshihiro Tokunaga, Takahiro Sasaki, Shunsuke Goto, Keishi Adachi, Yukimi Sakoda, and Koji Tamada
- 149 Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice**
Xin Chen, Yanmin Chen, Rong Liang, Lanxin Xiang, Jingwen Li, Yuankui Zhu, Huixia He, Le Huang, Dianbao Zuo, Weihang Li, Xinjun Liang, Shuang Dong, Sheng Hu, Mitchell Ho, and Mingqian Feng
- 159 The Road to Personalized Myeloma Medicine: Patient-specific Single-domain Antibodies for Anti-idiotypic Radionuclide Therapy**
Janik Puttemans, Benoit Stijlemans, Marleen Keyaerts, Sam Vander Meeren, Wim Renmans, Karel Fostier, Pieterjan Debie, Heleen Hanssens, Magdalena Rodak, Marek Pruszyński, Kim De Veirman, Karin Vanderkerken, Tony Lahoutte, Alfred Morgenstern, Frank Bruchertseifer, Nick Devoogdt, and Matthias D'Huyvetter

TARGETING DRUG RESISTANCE

- 170 Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in *H/NRAS^{G61X}* Mutant Rhabdomyosarcoma**
Natalia Garcia, Vanessa Del Pozo, Marielle E. Yohe, Craig M. Goodwin, Terry J. Shackelford, Long Wang, Kunal Baxi, Yidong Chen, Anna T. Rogojina, Sara M. Zimmerman, Cody J. Peer, William D. Figg, Myron S. Ignatius, Kris C. Wood, Peter J. Houghton, and Angelina V. Vaseva

- 184 Overcoming Gemcitabine Resistance in Pancreatic Cancer Using the BCL-X_L-Specific Degradator DT2216**
Dinesh Thummuri, Sajid Khan, Patrick W. Underwood, Peiyi Zhang, Janet Wiegand, Xuan Zhang, Vivekananda Budamagunta, Amin Sobh, Abderrahmane Tagmount, Alexander Loguinov, Andrea N. Riner, Ashwin S. Akki, Elizabeth Williamson, Robert Hromas, Christopher D. Vulpe, Guangrong Zheng, Jose G. Trevino, and Daohong Zhou
- 193 Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer**
Elia Farah, Zhuangzhuang Zhang, Sagar M. Utturkar, Jinpeng Liu, Timothy L. Ratliff, and Xiaoqi Liu
- 206 Anastrozole Regulates Fatty Acid Synthase in Breast Cancer**
Junmei Cairns, James N. Ingle, Krishna R. Kalari, Matthew P. Goetz, Richard M. Weinshilboum, Huanyao Gao, Hu Li, Mehrab Ghanat Bari, and Liewei Wang

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

- 217 HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study**
Takuya Osada, Erika J. Crosby, Kensuke Kaneko, Joshua C. Snyder, Joshua D. Ginzl, Chaitanya R. Acharya, Xiao-Yi Yang, Thomas J. Polascik, Ivan Spasojevic, Rendon C. Nelson, Amy Hobeika, Zachary C. Hartman, Leonard M. Neckers, Andre Rogatko, Philip F. Hughes, Jiaoti Huang, Michael A. Morse, Timothy Haystead, and H. Kim Lyerly
- 227 Association of Homologous Recombination-DNA Damage Response Gene Mutations with Immune Biomarkers in Gastroesophageal Cancers**
Michael Cerniglia, Joanne Xiu, Axel Grothey, Michael J. Pishvaian, Yasmine Baca, Jimmy J. Hwang, John L. Marshall, Ari M. VanderWalde, Anthony F. Shields, Heinz-Josef Lenz, W. Michael Korn, Mohamed Salem, Philip A. Philip, Richard M. Goldberg, Jia Zeng, and Sunnie S. Kim

LETTERS TO THE EDITOR


- 237 Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Letter**
David M. Goldenberg, Robert M. Sharkey, Serengulam V. Govindan, and Thomas M. Cardillo
- 238 Novel Peptide Camptothecin Drug-linkers for Potent ADCs—Reply**
Scott Jeffrey and Peter Senter
- 239 Acknowledgment to Reviewers**

TABLE OF CONTENTS

ABOUT THE COVER

In this issue of *Molecular Cancer Therapeutics*, Jensen-Pergakes and colleagues disclose the structure of the SAM-competitive PRMT5 inhibitor PF-06939999. This crystal structure of PRMT5/MEP50 shows PF-06939999 (cyan) bound to a large portion of the S-adenosyl-homocysteine (SAH, in magenta) binding pocket. PF-06939999 demonstrated potent anti-proliferative activity in preclinical NSCLC tumors. Read the full study on page 3.

doi: 10.1158/1535-7163.MCT-21-1-CVR



Molecular Cancer Therapeutics

21 (1)

Mol Cancer Ther 2022;21:1-242.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/21/1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/21/1>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.